



US009750808B2

(12) **United States Patent**
Krause et al.

(10) **Patent No.:** **US 9,750,808 B2**

(45) **Date of Patent:** ***Sep. 5, 2017**

(54) **FORMULATION OF HUMAN ANTIBODIES
FOR TREATING TNF-ALPHA ASSOCIATED
DISORDERS**

C07K 2317/21; C07K 2317/76; C07K
2317/94; A61K 39/39591; A61K 39/3955;
A61K 2039/505; A61K 39/39533; A61K
39/395

(71) Applicant: **AbbVie Biotechnology Ltd**, Hamilton
(BM)

See application file for complete search history.

(72) Inventors: **Hans-Juergen Krause**, Gruenstadt
(DE); **Lisa Baust**, Ludwigshafen (DE);
Michael Dickes, Rodersheim-Gronau
(DE)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(73) Assignee: **ABBVIE BIOTECHNOLOGY LTD.**,
Hamilton (BM)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

| | | | |
|-----------|----|---------|--------------------|
| 4,091,089 | A | 5/1978 | Chichibu |
| 4,597,966 | A | 7/1986 | Zolton et al. |
| 4,897,465 | A | 1/1990 | Cordle et al. |
| 5,096,885 | A | 3/1992 | Pearlman |
| 5,231,024 | A | 7/1993 | Moeller et al. |
| 5,237,054 | A | 8/1993 | Brinks et al. |
| 5,358,708 | A | 10/1994 | Patel et al. |
| 5,608,038 | A | 3/1997 | Eibl et al. |
| 5,654,403 | A | 8/1997 | Smith et al. |
| 5,792,838 | A | 8/1998 | Smith et al. |
| 5,945,098 | A | 8/1999 | Sarno et al. |
| 5,998,378 | A | 12/1999 | Kriegler et al. |
| 6,015,557 | A | 1/2000 | Tobinick et al. |
| 6,024,938 | A | 2/2000 | Corbo et al. |
| 6,090,382 | A | 7/2000 | Salfeld et al. |
| 6,165,467 | A | 12/2000 | Hagiwara et al. |
| 6,171,586 | B1 | 1/2001 | Lam et al. |
| 6,177,077 | B1 | 1/2001 | Tobinick |
| 6,235,281 | B1 | 5/2001 | Stenzel et al. |
| 6,238,664 | B1 | 5/2001 | Hellerbrand et al. |
| 6,252,055 | B1 | 6/2001 | Relton |
| 6,258,562 | B1 | 7/2001 | Salfeld et al. |
| 6,267,958 | B1 | 7/2001 | Andya et al. |
| 6,281,336 | B1 | 8/2001 | Laursen et al. |
| 6,379,666 | B1 | 4/2002 | Tobinick |

(Continued)

(21) Appl. No.: **15/418,460**

(22) Filed: **Jan. 27, 2017**

(65) **Prior Publication Data**

US 2017/0151329 A1 Jun. 1, 2017

Related U.S. Application Data

(63) Continuation of application No. 15/095,393, filed on
Apr. 11, 2016, which is a continuation of application
No. 14/826,357, filed on Aug. 14, 2015, now Pat. No.
9,327,032, which is a continuation of application No.
14/558,182, filed on Dec. 2, 2014, now Pat. No.
9,114,166, which is a continuation of application No.
14/453,490, filed on Aug. 6, 2014, now Pat. No.
8,916,158, which is a continuation of application No.
14/322,581, filed on Jul. 2, 2014, now Pat. No.
8,911,741, which is a continuation of application No.
14/091,938, filed on Nov. 27, 2013, now Pat. No.
8,795,670, which is a continuation of application No.
13/471,820, filed on May 15, 2012, now Pat. No.
8,932,591, which is a continuation of application No.
10/525,292, filed as application No. PCT/IB03/04502
on Aug. 15, 2003, now Pat. No. 8,216,583, which is
a continuation of application No. 10/222,140, filed on
Aug. 16, 2002, now abandoned.

FOREIGN PATENT DOCUMENTS

| | | |
|----|---------|---------|
| CA | 2241319 | 1/1997 |
| EP | 0186833 | 7/1986 |
| EP | 0218868 | 4/1987 |
| EP | 0230574 | 8/1987 |
| EP | 0374510 | 6/1990 |
| EP | 0419251 | 3/1991 |
| EP | 0453898 | 10/1991 |
| EP | 0486526 | 5/1992 |
| EP | 0417191 | 10/1993 |
| EP | 0585705 | 3/1994 |

(Continued)

OTHER PUBLICATIONS

“Campath®”, Physicians’ Desk Reference, 992-995, 56th ed.
(2002) (6 pages).

“Nutropin AQ®”, Physicians’ Desk Reference, 1420-1423, 56th ed.
(2002) (6 pages).

“Orthoclone OKT® 3 Sterile Solution,” Physicians’ Desk Refer-
ence, 2498-2502, 56th ed. (2002) (7 pages).

(Continued)

Primary Examiner — Bridget E Bunner

(74) *Attorney, Agent, or Firm* — Ropes & Gray LLP;
James F. Haley, Jr.; Brian M. Gummow

(51) **Int. Cl.**
A61K 39/395 (2006.01)
C07K 16/00 (2006.01)
C07K 16/22 (2006.01)
C07K 16/24 (2006.01)
A61K 47/26 (2006.01)
C07K 14/525 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 39/39591** (2013.01); **A61K 47/26**
(2013.01); **C07K 16/241** (2013.01); **C07K**
2317/21 (2013.01); **C07K 2317/76** (2013.01);
C07K 2317/92 (2013.01)

(58) **Field of Classification Search**
CPC .. **C07K 16/241**; **C07K 16/24**; **C07K 2316/96**;

(57) **ABSTRACT**

A liquid aqueous pharmaceutical formulation is described
which has a high protein concentration, a pH of between
about 4 and about 8, and enhanced stability.

30 Claims, No Drawings